Postnatal expression profiles of atypical cadherin FAT1 suggest its role in autism

Jeannine A Frei
Cheryl J Brandenburg
Jonathan E Nestor
Didier M Hodzic
Celine Plachez

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
RESEARCH ARTICLE

Postnatal expression profiles of atypical cadherin FAT1 suggest its role in autism

Jeannine A. Frei1, Cheryl J. Brandenburg1,2, Jonathan E. Nestor1, Didier M. Hodzic3, Celine Plachez1,4, Helen McNeill3, Derek M. Dykxhoorn5, Michael W. Nestor1, Gene J. Blatt1 and Yu-Chih Lin1,∗

ABSTRACT
Genetic studies have linked FAT1 (FAT atypical cadherin 1) with autism spectrum disorder (ASD); however, the role that FAT1 plays in ASD remains unknown. In mice, the function of Fat1 has been primarily implicated in embryonic nervous system development with less known about its role in postnatal development. We show for the first time that FAT1 protein is expressed in mouse postnatal brains and is enriched in the cerebellum, where it localizes to granule neurons and Golgi cells in the granule layer, as well as inhibitory neurons in the molecular layer. Furthermore, subcellular characterization revealed FAT1 localization in neurites and soma of granule neurons, as well as being present in the synaptic plasma membrane and postsynaptic densities. Interestingly, FAT1 expression was decreased in induced pluripotent stem cell (iPSC)-derived neural precursor cells (NPCs) from individuals with ASD. These findings suggest a novel role for FAT1 in postnatal development and may be particularly important for cerebellum function. As the cerebellum is one of the vulnerable brain regions in ASD, our study warrants further investigation of FAT1 in the disease etiology.

KEY WORDS: FAT1, Cadherin, Cerebellum, Granule cells, Autism, Neural precursor cells

INTRODUCTION
The cadherin superfamily of cell adhesion molecules consists of more than one hundred members that are subdivided into distinct subfamilies, including classical type I and type II cadherins, clustered and non-clustered protocadherins, and atypical FAT cadherins (Hulpiau and van Roy, 2009; Hirano and Takeichi, 2012). Cadherins play widespread roles throughout brain development as they have been implicated in neurogenesis, migration, axon outgrowth, target recognition, synaptogenesis, and synaptic plasticity (Hirano and Takeichi, 2012; Friedman et al., 2015). The vertebrate atypical FAT cadherin family, consisting of four members (FAT1-4) is distinguished from other cadherin subfamilies by their unusually large extracellular domains containing 32 to 34 cadherin repeats (Sadeqzadeh et al., 2014). These extracellular cadherin domains (ECDs) are highly similar among the four FAT cadherins; however, the cytoplasmic domain is less conserved and likely reflects the specific functions of each FAT cadherin (Sadeqzadeh et al., 2014). Depending on the tissue, FAT cadherins act both synergistically and antagonistically to exert their functions (Saburi et al., 2012). Studies in vertebrates have shown that FAT cadherins play critical roles in early development of the nervous system. Rather than conveying molecular codes that specify cell–cell contacts similar to the function of classical cadherins, FAT cadherins are particularly important in the establishment of polarity, including morphogenesis of epithelial structures, neuronal migration, and cellular proliferation (Avilés and Goodrich, 2017).

FAT1 and FAT4 are the most frequently studied members of the family, although all four FAT cadherins have been implicated in cancer development (Sadeqzadeh et al., 2014). Recently, genetic variations in FAT1 have been associated with neurological disorders, such as bipolar disorder (Blair et al., 2006; Abou Jamra et al., 2008) and autism spectrum disorder (ASD) (Hussman et al., 2011; Cukier et al., 2014; Neale et al., 2012). ASD contains a range of neurodevelopmental conditions categorized by difficulties in social interaction and communication, as well as repetitive behaviors (American Psychiatric Association, 2013). To date, about 1 in 54 children in the United States are diagnosed with ASD (Maenner et al., 2020). Although ASD is characterized by high genetic and phenotypic heterogeneity, many of the genes associated with ASD converge into selective cellular pathways, including those that regulate neural circuit formation (Lin et al., 2016; Hussman et al., 2011; Betancur et al., 2009). Since FAT1 has been associated with ASD, evaluating how this protein affects brain development and regulates circuit formation is important to understand the etiology of this neurodevelopmental disorder.

During embryogenesis, FAT1 is predominantly expressed in epithelial cells and in the central nervous system (CNS) (Ponassi et al., 1999; Dunne et al., 1995). In the developing CNS, FAT1 is expressed in the neural epithelium, and later in the proliferating...
In contrast to its high expression during embryogenesis, much less is known about the expression and distribution of FAT1 later in development. Depending on the tissue and species investigated, some studies have reported downregulated or absence of FAT1 expression in adult tissue (Ponassi et al., 1999; Dunne et al., 1995), while others have observed low-levels of postnatal expression (Ponassi et al., 1999; Cox et al., 2000). To better understand FAT1 expression beyond embryonic stages, we conducted a detailed analysis of FAT1 protein expression during postnatal brain development in mice at the brain area-, cellular-, and subcellular levels. Furthermore, we investigated the association of FAT1 with ASD by analyzing its expression in neural precursor cells (NPCs) differentiated from induced pluripotent stem cells (iPSCs) derived from individuals with autism compared to those from control individuals. Our findings suggest a potential function of FAT1 in the cerebellum during early postnatal development and strengthen its association with ASD by showing altered expression levels of FAT1 in autism-specific NPCs.

RESULTS AND DISCUSSION
The postnatal cerebellum exhibits high levels of FAT1 protein
To thoroughly investigate the distribution of FAT1 in the brain, we analyzed its developmental expression profile in wild-type C57BL/6 mouse brains. The specificity of the anti-FAT1 antibody was first validated by Western blot using whole cell lysates from vascular smooth muscle cells from wild-type and FAT1 knockout mice. The anti-FAT1 antibody recognizes a band above 460 kDa that is not detectable in the FAT1 knockout tissue (Fig. 1A). This antibody was then used to investigate the temporal expression of FAT1 in whole brain tissue of mice at different developmental ages ranging from embryonic day 14 (E14) to adulthood (Fig. 1B). FAT1 was highly expressed at E14, which is consistent with previous studies showing elevated Fatl mRNA expression in the neuro-epithelium and proliferating germinal zones in the embryonic mouse brain (Ciani et al., 2003; Badouel et al., 2015). At birth, FAT1 protein levels dropped but exhibited a second peak at postnatal day 14 (P14). After P21, FAT1 levels gradually declined and reached lower levels in adulthood compared to E14.

We next analyzed FAT1 expression in different brain areas, including cortex, hippocampus, cerebellum, and thalamus/stratum at P7 and P14 (Fig. 1C). Intriguingly, FAT1 was highly expressed in the cerebellum compared to the other brain areas at both time points. Temporal expression of FAT1 in the cerebellum revealed a significant increase from P1 to P21 (Fig. 1D). We then examined the expression levels of FAT1 in cerebellar granule cells that make up the majority of cells in the cerebellum. Granule cells were dissected from P7 mouse cerebellum and cultured for 1, 3, 7, and 14 days in vitro (DIV). We found a gradual increase of FAT1 expression from 1 DIV to 14 DIV (Fig. 1E), recapitulating the expression seen in cerebellum tissue. Together, these findings suggest that FAT1 plays a crucial role in the development of cerebellar granule cells.

FAT1 is expressed in granule cells and interneurons in the cerebellum and hippocampus
To further investigate which cell types express FAT1, we performed histochemical examination of FAT1 on sagittal sections of P14 wild-type C57BL/6 mouse brains. FAT1 antibody was first evaluated on FAT1 wild-type and knockout tissues to confirm its specificity (Fig. 2A, B). DAB-staining revealed that FAT1 was expressed by cells throughout the whole brain, including cortex, hippocampus, and cerebellum (Fig. 2C–E). Neutral red staining was performed to highlight the variable cell densities in different areas of the brain (Fig. 2F–II). Interestingly, FAT1 was particularly enriched in the areas of high cell densities, such as the cerebellar granule cells (Fig. 2D, D') and the dentate gyrus granule cells (Fig. 2E). In addition, FAT1 was detectable in interneurons in both the cerebellum and hippocampus, including Golgi cells in the cerebellar granule cell layer and other interneurons in the molecular layer, as well as in hippocampal interneurons in CA1, CA2, and CA3 regions (Fig. 2D, E). FAT1 was not detectable in Purkinje cells or pyramidal cells in CA regions (Fig. 2D, E). We performed immunofluorescence staining to confirm the cell type of cerebellar neurons expressing FAT1 in sagittal sections of P14 mouse brains and co-stained the tissue with calbindin, a marker for Purkinje cells, and parvalbumin (PV), a marker for Purkinje cells and interneurons residing in the molecular layer (Fig. 2L). In line with the DAB staining, FAT1 was expressed in granule cells and Golgi cells in the granule cell layer (GCL). Golgi cells contact and modulate the excitatory granule cell-mossy fiber synapses in the cerebellar glomeruli, thus regulating input into the cerebellum (Hashimoto and Hibi, 2012; Hámori and Szentágothai, 1966; Hámosi and Somogyi, 1983; Jakab and Hámosi, 1988). Furthermore, FAT1 was expressed in PV-positive cells in the molecular layer (ML). Interestingly, FAT1 immunofluorescence was detectable around calbindin- and PV-positive cells located in the Purkinje cell layer (PCL). The presence of FAT1 in PV+-interneurons, e.g. basket and/or stellate cells, as well as around Purkinje cells, indicate that FAT1 may be present in axons of interneurons connecting to the soma of Purkinje cells, such as basket cells. Basket cells inhibit Purkinje cell firing and, as a result, influence cerebellar cortical output to the deep cerebellar nuclei. Based on its increased expression during postnatal cerebellar development, FAT1 has the potential to regulate the development and/or maintenance of various neural circuits in the cerebellum, including inhibitory synapses on granule cells and Purkinje cells.

FAT1 localizes to neurites and soma of cultured cerebellar granule cells
We next investigated the subcellular localization of FAT1 in cerebellar granule cells by immunocytochemistry. FAT1 colocalized at the MAP2-positive dendrites of cerebellar granule neuron cultured for 14 DIV (Fig. 3A). FAT1 was also present on the soma and nucleus of cerebellar granule neurons cultured for 14 DIV (Fig. 3A). In addition, expression of FAT1 in cerebellar granule neurons cultured for 14 DIV (Fig. 3A). In conclusion, we have shown that FAT1 is an important molecule in the development of cerebellar granule cells and that it plays a crucial role in the formation of excitatory synapses in the cerebellum.
Fig. 1. The postnatal cerebellum exhibits high levels of FAT1 protein. (A) The specificity of FAT1 antibody was tested by Western blot. Lysates from vascular smooth muscle cells isolated from aortas of wild-type (WT) and FAT1 knockout (KO) mice were probed with anti-FAT1 antibody. The antibody recognizes one band around 500 kDa, the predicted size of FAT1, in the WT but not KO lysate. (B) Temporal expression profile of FAT1 in mouse whole brain collected at E14, P1, P7, P14, P21 and 5-month-old adults. N=6 whole brains per age from three independent litters. (C) Spatial expression profile of FAT1 in cortex, hippocampus, cerebellum and thalamus/striatum at P7 and P14 of mouse brain development. P7: **p=0.0002, ****p<0.0001, P14: ****p=0.0002 CX versus CB, p=0.0165 HC versus CB, p=0.0005 CB versus Th/St; one-way ANOVA with Tukey’s multiple comparison test. N=4 samples per brain area with 2–3 pooled brain areas per sample. (D) Temporal expression profile of FAT1 in the cerebellum at P1, P7, P14 and P21. *p=0.0116, **p=0.0014, ***p=0.0002; one-way ANOVA with Tukey’s multiple comparison test. N=4 samples per time point with 2–3 pooled cerebells per sample. (E) Temporal expression profile of FAT1 in cultured cerebellar granule neurons harvested at 1, 3, 7, and 14 DIV. **p=0.0094; one-way ANOVA with Tukey’s multiple comparison test. N=3 independent cultures.
Fig. 2. FAT1 is expressed in granule cells and interneurons in the cerebellum and hippocampus. (A) The specificity of FAT1 antibody was tested on sagittal sections of embryonic eyes from E13.5 FAT1 KO and WT mice. Scale bars: 100 μm. (B) Magnification of boxed areas depicted in A. FAT1 (green) colocalizes with phalloidin-stained actin (red) in WT but not KO eyes. Sections were counter-stained with DAPI (blue). Scale bars: 50 μm. (C–H) DAB immunostaining of FAT1 and (F–H) FAT1-DAB and neutral red co-staining on P14 mouse brain sagittal sections. Magnifications of cerebellum are depicted in (D), (D'), (G) and (G') and magnifications of hippocampus are depicted in (E) and (H). FAT1 is expressed in the cerebellum (D,D') in the surrounding but not in the soma of Purkinje cells (box 1, arrowheads), in the granule cell layer (box 2) in granule cells (asterisk) and Golgi cells (arrows), and in interneurons in the molecular layer (box 3, open arrowheads). FAT1 is also expressed in the hippocampus (E) in interneurons (box 1, open arrowheads) and in granule cells of the dentate gyrus (box 2, asterisk). Note that FAT1 is enriched in cell dense structures of cerebellar granule layer (G,G') and hippocampal dentate gyrus (H). Scale bars: 1 mm (C,D,F,G), 0.5 mm (E,H), 100 μm (D',G'), 50 μm (box 1–3 in D', box 1,2 in E). (I) Sagittal sections of P14 cerebellum co-immunostained for FAT1 (red), calbindin (blue), and parvalbumin (PV; green). Dashed lines indicate layers: GCL, granule cell layer; PCL, Purkinje cell layer; ML, molecular layer. Scale bar: 100 μm. (J) Magnification of GCL, PCL, and ML depicted in merged image in I. Scale bar: 50 μm. FAT1 is expressed in granule cells (asterisk) and Golgi cells (arrows) in the GCL, around calbindin- and PV-positive Purkinje cells (open arrowheads) in the PCL, and PV-positive interneurons (arrowheads) in the ML.
Fig. 3. FAT1 localizes to neurites and soma of cerebellar granule cells. Confocal images of cerebellar granule cell cultures fixed at 14 DIV and immunostained with FAT1 (cyan) together with different neuronal and synaptic markers (magenta), including (A) MAP2, (B) Tau, (C) vGlut1, and (D) PSD-95. FAT1 is expressed in dendrites, axons, and soma and localizes to vGlut1 and PSD-95 puncta. Scale bars: 10 μm, 2 μm (magnifications in B–D).
(E) Synaptic fractionation of P21 cerebellar tissue was performed to determine the subcellular localization of FAT1. Western blots were probed, stripped, and reprobed with markers PSD-95, syntaxin-1 and β-actin to confirm successful separation and purity of different fractions. Total, total protein input; P1, nuclear; S1, cytosol membranes; P2, crude synaptosome; S2, cytosol/light membranes; P3, synaptosome; SPM, synaptic plasma membrane; PSD, postsynaptic density; S3, synaptic vesicles. *p<0.00422; one-way ANOVA with Tukey’s multiple comparison test, N=6 mice, two pooled cerebellums per sample.
MATERIALS AND METHODS

Animals
C57BL/6 mice were obtained from the animal facility of the University of Maryland School of Medicine Program in Comparative Medicine (Baltimore, MD, USA). Mice were housed and cared for by the AAALAC accredited program of the University of Maryland School of Medicine. Female mice were group-housed and male mice were singly housed with ad libitum food and water accessibility under a standard 12-h light/dark cycle. Mice of both sexes were used for biochemical analyses and neuronal cell culture preparation. All experiments were performed in accordance with the animal care guidelines of the National Institute of Health and were reviewed and approved by the Institutional Care and Use Committees (IACUC) of the University of Maryland School of Medicine and the Hussman Institute for Autism. Fat1 KO mice (Gee et al., 2016) were housed at the Mouse Genetics Core facility at Washington University School of Medicine in St Louis and cared for by the Division of Comparative Medicine following animal protocols that strictly adhered to the ethical and sensitive care and use of animals in research. All procedures were approved by the Washington University School of Medicine Animal Studies Committee.

Antibodies
Antibodies used for biochemical analysis and immunostainings are listed in Table 1.

Western blot
Whole brains and different brain areas, including cortex, hippocampus, cerebellum and thalamus/striatum, were collected from both sexes of C57BL/6 mice at different developmental ages: E14, P1, P7, P14, P21 and adult (5-month-old) mice. Mice were euthanized and brains were quickly removed and dissected followed by snap freezing in liquid nitrogen. All tissues were homogenized in RIPA buffer (Cell Signaling Technology Cat# 9806S) supplemented with PMSF (Cell Signaling Technology Cat#8553S) and protease/phosphatase inhibitor cocktail (Thermo Fisher Scientific Cat#78442). FAT1 knockout and wild-type tissue lysates from vascular smooth muscle cells isolated from aortas of Fat1^lox/lox (control) or Tagln-Cre;Fat1^lox/lox (FAT1 knockout) of 5-week-old mice were a gift from Dr. Nicholas Sibinga (Albany Medical College). For Western blot analysis, cells were plated at a density of 250,000/cm² and harvested at different time points: 1, 3, 7 and 14 DIV. At the desired DIV, cells were lysed in RIPA buffer (Cell Signaling Technology Cat# 9806S) supplemented with PMSF (Cell Signaling Technology Cat#8553S) and protease/phosphatase inhibitor cocktail (Thermo Fisher Scientific Cat#78442). To determine protein concentration the Pierce BCA protein assay kit (Thermo Fisher Scientific Cat#23227) was used and measurements were performed by the Tecan Spark 10 M multimode microplate reader. For immunofluorescence staining, cerebellar granule cells were cultured on coverslips in 24-well plates at a density of 500,000 cells/well.
## Table 1. Primary and secondary antibodies used in this study

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Host, isotype</th>
<th>Immunogen</th>
<th>Source</th>
<th>Cat#</th>
<th>Clone no./RRID</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAT1</td>
<td>Rabbit, IgG</td>
<td>aa 4450-4500,</td>
<td>Bethyl Laboratories</td>
<td>A304-402A RRID:AB_2620597</td>
<td></td>
<td>1:500 (WB), 1:2000 (DAB), 1:1000 (IHC), 1:200 (ICC)</td>
</tr>
<tr>
<td>PSD-95</td>
<td>Mouse, IgG&lt;sub&gt;2a&lt;/sub&gt;</td>
<td>aa 77-299, Human</td>
<td>Neuro Mab</td>
<td>75-028  RRID:AB_2307331</td>
<td></td>
<td>1:100,000 (WB), 1:80 (ICC)</td>
</tr>
<tr>
<td>Syntaxin-1</td>
<td>Mouse, IgG&lt;sub&gt;2a&lt;/sub&gt;</td>
<td>N-terminus, Rat</td>
<td>Synaptic Systems</td>
<td>110111  RRID:AB_887848 78.3</td>
<td></td>
<td>1:10,000 (IHC)</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Rabbit, IgG</td>
<td>C-terminus, Human</td>
<td>Cell Signaling Technology</td>
<td>5174    RRID:AB_10622025</td>
<td></td>
<td>1:1000 (IHC)</td>
</tr>
<tr>
<td>β-actin</td>
<td>Mouse, IgG&lt;sub&gt;2a&lt;/sub&gt;</td>
<td>N-terminus</td>
<td>Millipore Sigma</td>
<td>A5316   RRID:AC-74</td>
<td></td>
<td>1:5000 ( ICC)</td>
</tr>
<tr>
<td>β-tubulin III</td>
<td>Mouse, IgG&lt;sub&gt;2a&lt;/sub&gt;</td>
<td>aa 438-450, Human</td>
<td>Millipore Sigma</td>
<td>T8578   RRID:AB_1841228</td>
<td></td>
<td>1:4000 (ICC)</td>
</tr>
<tr>
<td>Calbindin</td>
<td>Mouse, IgG&lt;sub&gt;1&lt;/sub&gt;</td>
<td>Calbindin D-28k chicken</td>
<td>Swant</td>
<td>300     RRID:AB_10000347</td>
<td></td>
<td>1:1000 (ICC)</td>
</tr>
<tr>
<td>Parvalbumin</td>
<td>Guinea Pig, IgG</td>
<td>Reombinant mouse parvalbumin</td>
<td>Swant</td>
<td>GP-72    RRID:AB_2665495</td>
<td></td>
<td>1:2000 (ICC)</td>
</tr>
<tr>
<td>MAP2</td>
<td>Mouse, IgG&lt;sub&gt;1&lt;/sub&gt;</td>
<td>Rat</td>
<td>Millipore Sigma</td>
<td>M9942   RRID:AB_477256</td>
<td></td>
<td>1:1000 (ICC)</td>
</tr>
<tr>
<td>Tau</td>
<td>Mouse, IgG&lt;sub&gt;2a&lt;/sub&gt;</td>
<td>aa 3-214, Mouse</td>
<td>Synaptic Systems</td>
<td>314011  RRID:AB_1085762</td>
<td></td>
<td>1:500 (ICC)</td>
</tr>
<tr>
<td>vGlut1</td>
<td>Mouse, IgG&lt;sub&gt;1&lt;/sub&gt;</td>
<td>aa 542-560, rale</td>
<td>Synaptic Systems</td>
<td>135011  RRID:AB_2884913</td>
<td></td>
<td>1:500 (ICC)</td>
</tr>
</tbody>
</table>

**Secondary antibodies**

- **anti-rabbit IgG, HRP conjugate**
- **anti-mouse IgG, HRP conjugate**
- **anti-rabbit Alexa488**
- **anti-mouse Alexa568**
- **anti-mouse Alexa647**
- **Anti-rabbit Alexa546**
- **Anti-mouse Alexa405**
- **Anti-quinae pig Alexa488**
- **Anti-rabbit Fab-Alexa 488**
- **Anti-rabbit Biotin-SP**

(Bio-Rad). Intensities were normalized to GAPDH, β-actin, or β-tubulin III signal as appropriate.

**Immunohistochemistry**

To confirm the specificity of FAT1 antibody, dissected E13.5 FAT1 wild-type and knockout mouse embryos were fixed in 4% paraformaldehyde for 24 h, transferred to 30% sucrose for two days, and embedded in OCT for sectioning at 20 μm on a cryostat. Sections were rinsed and incubated with secondary antibody for 1 h at room temperature. Sections were then washed and incubated with primary antibody diluted in 3% donkey serum in TBS-T for 2 h at room temperature followed by incubation for 30 min with secondary antibody conjugated to EnVision (Dako) or Alexa Fluor 488 (Invitrogen), respectively. Sections were then rinsed and mounted with secondary antibody for visualization.

cerebellum were cut on a Leica cryostat and sections were stored in glycerol cryoprotectant. Sections were rinsed of cryoprotectant three times for 2 min in a scientific microwave (Ted Pella) at 35°C and 150 watts (all following rinses were performed this way). Sections were blocked with 5% donkey serum in TBS-T for 30 min prior to incubation with primary antibody diluted in 5% donkey serum/ TBS-T for 1 h at room temperature followed by incubation for 47 h at 4°C. Sections were rinsed and incubated with secondary antibody for 1 h at room temperature.
above using Alexa Fluor secondary antibodies for 3 h. Imaging was performed with a Zeiss Microbrightfield microscope and Stereoinvestigator software.

**Immunocytochemistry**

Cultured granule cell neurons were fixed with 4% paraformaldehyde at 14 DIV for 15 min. Cells were permeabilized with 0.1% Triton-X100 and blocked in 2.5% donkey serum/2.5% BSA for 1 h. Samples were incubated with primary antibodies overnight at 4°C followed by incubation with secondary antibodies for 1 h at room temperature. For PSD-95/FAT1 co-staining, 14 DIV granule cells were fixed in 4% paraformaldehyde/4% sucrose for 10 min. Cells were washed in PBS/0.1 M glycine and permeabilized in 0.3% Triton-X100 in PBS/glycine for 20 min. Samples were blocked in 10% donkey serum/0.2% Triton-X100 in PBS/glycine for 20 min. Cells were incubated with primary antibodies in 5% donkey serum/0.1% Triton-X100 in PBS/glycine overnight at 4°C followed by incubation with secondary antibodies for 1 h at room temperature. Samples were washed in PBS before mounting with Prolong Diamond Antifade mounting medium (Thermo Fisher Scientific Cat#: P36934). Images were taken using a Zeiss LSM-780 scanning confocal microscope with a 63× objective/1.40 plan-apochromat oil and 4× zoom.

**Synaptic fractionation**

Synaptic fractionation of cerebellar tissue was performed using a protocol for forebrain fractionation published by Bermejo et al. (Bermejo et al., 2014). In brief, cerebella from P21 mice were quickly dissected on ice followed by homogenization in 0.2 M sucrose in 4 mM HEPES (pH 7.4) at 900 rpm with 12 strokes with a glass-Teflon tissue homogenizer. Low-speed centrifugation at 900 × g for 10 min separated nuclear fraction (P1) from supernatant (S1) that was collected and re-centrifuged at 10,000 × g for 15 min to yield crude synaptosomal fraction (P2) and cytosol/light membranes in the supernatant (S2). Double-distilled H2O was added to synaptosomal fraction (P2) for hypo-osmotic lysis followed by centrifugation at 25,000 × g for 20 min to collect pelletted synaptosomes (P3) and vesicular fraction (S3). A discontinuous sucrose gradient was prepared and ultracentrifugation of the gradient at 150,000 × g for 2 h was performed to yield synaptic plasma membrane (SPM) fraction from synaptosomes (P3). The SPM fraction was harvested and re-centrifuged at 200,000 × g for 30 min. Postasymmetric (PSD) fraction was prepared by incubating SPM in 0.5% Triton-X100 for 15 min and centrifugation at 32,000 × g for 30 min. Western blot was performed to analyze FAT1 expression in different fractions. Intensities of FAT1-positive bands in SPM and PSD fractions were normalized to the total protein input.

**Table 2. Information of control and autism-derived iPSC lines**

<table>
<thead>
<tr>
<th>Case ID</th>
<th>Gender</th>
<th>Diagnosis</th>
<th>Gene variants</th>
</tr>
</thead>
<tbody>
<tr>
<td>110</td>
<td>M</td>
<td>ASD</td>
<td>VPS13B, EFCA5, TRIM55</td>
</tr>
<tr>
<td>700</td>
<td>M</td>
<td>ASD</td>
<td>RBFOX1, CEP90, NINL, SOS2, TRIM55, ZMYND17, BTN2A2, MDC1, FBXO40, KIAA1949, SLC8A3, TSPYL5</td>
</tr>
<tr>
<td>725</td>
<td>M</td>
<td>ASD</td>
<td>CEP90, NINL, SOS2, TRIM55, ZMYND17, BTN2A2, MDC1, FBXO40, KIAA1949, SLC8A3, TSPYL5</td>
</tr>
<tr>
<td>732</td>
<td>M</td>
<td>ASD</td>
<td>CLCN2, F13A1, JARD2, STXBP5, C12orf73, C20orf118, FGD6</td>
</tr>
<tr>
<td>134</td>
<td>M</td>
<td>ASD</td>
<td>CP2, PRICKLE1, TOPORS</td>
</tr>
<tr>
<td>691</td>
<td>M</td>
<td>ASD</td>
<td>COL6A3, SLT73, C20orf65, AB13BP, UMG1</td>
</tr>
<tr>
<td>709</td>
<td>M</td>
<td>ASD</td>
<td>RBFOX1</td>
</tr>
<tr>
<td>710</td>
<td>M</td>
<td>ASD</td>
<td>RBFOX1</td>
</tr>
<tr>
<td>574</td>
<td>M</td>
<td>Neurotypical control</td>
<td>-</td>
</tr>
<tr>
<td>321</td>
<td>M</td>
<td>Neurotypical control</td>
<td>-</td>
</tr>
<tr>
<td>322</td>
<td>M</td>
<td>Neurotypical control</td>
<td>-</td>
</tr>
<tr>
<td>324</td>
<td>M</td>
<td>Neurotypical control</td>
<td>-</td>
</tr>
</tbody>
</table>

Data were generated and obtained from the University of Miami John P. Hussman Institute for Human Genomics (Hussman et al., 2011; Cukier et al., 2014).

**Generation of human iPSC-derived cortical neural precursor cells**

Human iPSC lines were derived from peripheral blood mononuclear cells (PBMCs) isolated from whole blood obtained from eight healthy adults (DeRosa et al., 2018). The assignation of ASD, (3) an expert clinical determination of an ASD diagnosis was determined using DSM-V (American Psychiatric Association, 2013) criteria supported by the Autism Diagnostic Interview-Revised (ADI-R) (Lord et al., 1994), and (4) intelligence quotient (IQ) equivalent >5 or developmental level >18 months as determined by the Vineland Adaptive Behavior Scale (VABS; Sparrow et al., 2005). The ASD lines 110, 134, 691, 709, 725, 732 had been derived and validated by DeRosa et al., 2018 while lines 700 and 710 have been described in a recent study (Frei et al., 2020 preprint). Control samples (321, 322, 324, 574) were obtained following informed consent under an IRB approved protocol (University of Miami) from cognitively normal individuals that were between 18 and 30 years of age and had no history of ASD or other neurological disorders (e.g. schizophrenia, major depressive disorder). PBMCs were reprogrammed to iPSCs using the CytoTune iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific Cat#: A16517; DeRosa et al., 2012) according to the manufacturer’s protocol. The samples were screened for pluripotency and genomic stability according to the published protocol by DeRosa et al. (2018). iPSCs were plated onto mouse embryonic feeders (MEFs) and maintained for 7 days in mTeSR1 (StemCell Technologies Cat#:85850). Selected iPSC colonies showing proliferating cell clusters were selected and dissociated via a 7-min treatment with Accutase in the presence of 20 μM Y27632 (Stemgent Cat#:00901210) (Nader et al., 2015; Phillips et al., 2017).
the following: 1:1 mixture of DMEM/F12 (with L-Glutamine; Thermo Fisher Scientific Cat#12320033) and Neurobasal medium (minus phenol red; Thermo Fisher Scientific Cat#12348017), 0.5% N2 supplement (Thermo Fisher Scientific Cat#17502048), 1% B-27 supplement (Thermo Fisher Scientific Cat#12587010), 0.5% non-essential amino acids, 0.5% GlutaMAX (Thermo Fisher Scientific Cat#35050061), 1% Insulin-Transferrin-Selenium-A (Thermo Fisher Scientific Cat#41400045), 1% penicillin/streptomycin (Thermo Fisher Scientific Cat#15140122), 30 ng/ml tri-iodothyronine (Millipore Sigma Cat#T5397), 40 ng/ml thyroxine (Millipore Sigma Cat#F1775), 100 μg/ml bovine-serum albumen (Millipore Sigma Cat#A1611) 60 ng/ml progesterone (Millipore Sigma Cat#P8783), 16 μg/ml putrescine (Millipore Sigma Cat#P7505), 5 μg/ml N-acetyl-L-cysteine (Millipore Sigma Cat#A8199) and 5 μM forskolin (Millipore Sigma Cat#F6886). At 19 DIV NPCs were lysed in RIPA buffer (Cell Signaling Technologies Cat# 9806S) supplemented with PMSF (Cell Signaling Technologies Cat#5855S) and protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific Cat#78442) and triplicates of each control and autism line were analyzed by Western blot.

Statistical analysis
Unpaired two-tailed t-test was performed to compare two groups and one-way ANOVA with Tukey’s multiple comparison test was performed for comparison between three or four groups. p-values were considered significant if <0.05. Bar graphs are displayed as mean±standard error of the mean (s.e.m.). All p-values and n numbers as well as statistical tests performed are reported in the figure legends. Statistical analysis was performed using Graph Pad Prism 8 software (GraphPad Prism Software, RRID: SCR_002798).

Acknowledgements
We want to thank Drs Louis DeTella and Turhan Coksaygan at the University of Maryland School of Medicine for providing veterinary services and consultation. We also thank Dr Nicholas Sibonga from the Albert Einstein College of Medicine, New York, for kindly providing the FAT1 knockout and control tissues. Finally, we thank Dr John Hussman for the critical evaluation of this manuscript.

Competing interests
The authors declare no competing or financial interests.

Author contributions

Funding
This work was supported by Hussman Foundation (grants HIAS#15007 and HIAS#18005 to J.A.F., and HIAS#15003 and HIAS#18004 to Y.-C.L.).


